Mallinckrodt PLC spent $610,000 lobbying Congress in the first quarter of 2017, triple the amount the pharmaceutical firm spent on lobbying in 2015’s first quarter.
The company’s political action committee also has increased its contributions to congressional campaigns, donating $44,000 to lawmakers in the House and Senate in the first quarter, up nearly nine times from 2015.
Companies across the pharmaceutical industry have been increasing campaign donations and lobbying spending this year, according to data from Kaiser Health News. Donations to congressional lawmakers from pharmaceutical PACs were up 11 percent in the first quarter as compared to 2015.
David Maris, a Wells Fargo analyst who follows the pharmaceutical industry, told the New York Times that the stakes are high now for drug companies as President Donald Trump has joined Democrats in demanding action around drug costs.
A Mallinckrodt spokeswoman acknowledged that the company has increased its political spending, saying it “actively participates in the political process on issues that matter to us and our patients.” She also noted that Mallinckrodt’s PAC’s spending remains small compared to others in the industry.
Read more: St. Louis Business Journal